Glucocorticoid‐induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization
Open Access
- 30 October 2008
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 58 (11), 3485-3497
- https://doi.org/10.1002/art.23954
Abstract
Objective Glucocorticoid excess decreases bone mineralization and microarchitecture and leads to reduced bone strength. Both anabolic (parathyroid hormone [PTH]) and antiresorptive agents are used to prevent and treat glucocorticoid‐induced bone loss, yet these bone‐active agents alter bone turnover by very different mechanisms. This study was undertaken to determine how PTH and risedronate alter bone quality following glucocorticoid excess. Methods Five‐month‐old male Swiss‐Webster mice were treated with the glucocorticoid prednisolone (5 mg/kg in a 60‐day slow‐release pellet) or placebo. From day 28 to day 56, 2 groups of glucocorticoid‐treated animals received either PTH (5 μg/kg) or risedronate (5 μg/kg) 5 times per week. Bone quality and quantity were measured using x‐ray tomography for the degree of bone mineralization, microfocal computed tomography for bone microarchitecture, compression testing for trabecular bone strength, and biochemistry and histomorphometry for bone turnover. In addition, real‐time polymerase chain reaction (PCR) and immunohistochemistry were performed to monitor the expression of several key genes regulating Wnt signaling (bone formation) and mineralization. Results Compared with placebo, glucocorticoid treatment decreased trabecular bone volume (bone volume/total volume [BV/TV]) and serum osteocalcin, but increased serum CTX and osteoclast surface, with a peak at day 28. Glucocorticoids plus PTH increased BV/TV, and glucocorticoids plus risedronate restored BV/TV to placebo levels after 28 days. The average degree of bone mineralization was decreased after glucocorticoid treatment (−27%), but was restored to placebo levels after treatment with glucocorticoids plus risedronate or glucocorticoids plus PTH. On day 56, RT‐PCR revealed that expression of genes that inhibit bone mineralization (Dmp1 and Phex) was increased by continuous exposure to glucocorticoids and glucocorticoids plus PTH and decreased by glucocorticoids plus risedronate, compared with placebo. Wnt signaling antagonists Dkk‐1, Sost, and Wif1 were up‐regulated by glucocorticoid treatment but down‐regulated after glucocorticoid plus PTH treatment. Immunohistochemistry of bone sections showed that glucocorticoids increased N‐terminal Dmp‐1 staining while PTH treatment increased both N‐ and C‐terminal Dmp‐1 staining around osteocytes. Conclusion Our findings indicate that both PTH and risedronate improve bone mass, degree of bone mineralization, and bone strength in glucocorticoid‐treated mice, and that PTH increases bone formation while risedronate reverses the deterioration of bone mineralization.Keywords
This publication has 74 references indexed in Scilit:
- Tissue strain amplification at the osteocyte lacuna: A microstructural finite element analysisJournal of Biomechanics, 2007
- Teriparatide or Alendronate in Glucocorticoid-Induced OsteoporosisThe New England Journal of Medicine, 2007
- Is long-term glucocorticoid therapy associated with a high prevalence of asymptomatic vertebral fractures?Nature Clinical Practice Endocrinology & Metabolism, 2007
- Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral bloodJournal of Bone and Mineral Metabolism, 2006
- Glucocorticoids Act Directly on Osteoclasts to Increase Their Life Span and Reduce Bone DensityEndocrinology, 2006
- Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolismNature Genetics, 2006
- Glucocorticoids suppress bone formation via the osteoclastJCI Insight, 2006
- Increased adipogenesis in bone marrow but decreased bone mineral density in mice devoid of thyroid hormone receptorsBone, 2005
- Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosisBiochemical and Biophysical Research Communications, 2004
- Three small integrin‐binding ligand N‐linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinasesThe FASEB Journal, 2004